Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > 30s a little high Beech.
View:
Post by inspecthrgadget on Jul 23, 2020 3:37pm

30s a little high Beech.

People that took $12M without free warrant were saying 4 and then 3 cents. Other friend now buying said 5 cents and then under review and then slipped out of Alter-Cyte. Speaking of witch, has PWC accounting identified the unknown director with the 2%?

Why no farewell speech for Ed?  He was the fellow that said 2 to 1 ratios in favour of proposed treatments were common in confirmatory 28 day mortality trial affairs. 


The US has this buy the jewels and everyone has to play along. Did I mention the CTSO German Sepsis trial debacle or their current FDA suspended trial effort?  Nice to be punked by bullboard peeps!  $10 US and no gard data huh?  Another Kiacta Dredger?

Comment by Inca2020 on Jul 23, 2020 3:40pm
You are comparing apples to oranges. They've proven to make $50M canadian per year in revenue. 
Comment by inspecthrgadget on Jul 23, 2020 3:48pm
NO...they lost 20 M US last year Revenue can be expensive You stand guard feller We might ask Zacks for another " 2 for 1" I hope the rep understands the currency exchange this time lol I love bullboard FRAUD
Comment by Inca2020 on Jul 23, 2020 4:07pm
all the worse. I just looked it up. Net income was negative 20M net assets ~40M and revenue of ~25M. More rev than here either way. Only 40M shares our with 31M float and obviously way better volume on a much better exchange. What can I say.. their name is out there and they're doing a great job raising lots of capital at a generous valuation. Good for their shareholders.  
Comment by mercedesman on Jul 23, 2020 5:00pm
"...and revenue of ~25M. More rev than here either way" Yes more, especailly when CTSO recognizes grants as current revenue, and Spectral's $ 7M in non refundable payments from Baxter are treated as a Liability (or Deferred Revenue) and not recognized in current revenue except very ssssssssssssssloooooooooowly over a period of 9 years. Anyway it's more about future revenue and ...more  
Comment by daviking on Jul 23, 2020 7:09pm
SHEESH, MM, you forget who you were posting as AGAIN!!! Were you writing as IG or STT and forgot? If you are writing as MM why don't you just say: " see MY previous revenue post: mercedesman - (7/23/2020 5:00:40 PM) RE:RE:RE:RE:30s a little high Beech. "...and revenue of ~25M. More rev than here either way" Yes more, especailly when CTSO recognizes grants as current ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities